arrow
L

Liang Schweizer

Bristol-Myers Squibb
H指数:19
被引数:2,628

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors

基于模型的剂量优化:针对HFB200301(一种TNFR2激动剂单克隆抗体(mAb))的单药治疗及其与抗PD-1单克隆抗体tislelizumab(TIS)联合治疗,在晚期实体瘤患者(pts)中的应用

2024-09-010
PRE
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
2021-05-1163
OAAI
Sensitivity of liver cancer cell lines to B-catenin knock-down correlates with pathway activation
2018-07-010
PRE
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
2015-06-2621
OAAI
Androgen receptor antagonists: Lead optimization and preclinical pharmacology
2010-04-010
PRE